Alnylam says heart disease drug meets goal in late-stage trial

A label expansion could be around the corner for drug Onpattro after the pharmaceutical firm reports positive results for patients with a specific type of heart disease.

Photo: Martin Havtorn Petersen/MedWatch

Alnylam Pharmaceuticals Inc.’s Onpattro met the main goal of a late-stage trial in patients with a form of heart disease, paving the way for the company to seek wider approval from US regulators.

The drug is already cleared to treat nerve disease caused by transthyretin amyloidosis, a disorder where misfolded protein accumulates in certain tissues. Alnylam is now seeking to use the drug in people whose hearts can’t function properly because of deposits of the harmful material.

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

Further reading

Related articles

Latest news

See all jobs